U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C10H17N.H2O4S
Molecular Weight 400.5777
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMANTADINE SULFATE

SMILES

C1C2CC3CC1CC(C2)(C3)N.C1C2CC3CC1CC(C2)(C3)N.OS(=O)(=O)O

InChI

InChIKey=MYWTWSQFJLXGGQ-UHFFFAOYSA-N
InChI=1S/2C10H17N.H2O4S/c2*11-10-4-7-1-8(5-10)3-9(2-7)6-10;1-5(2,3)4/h2*7-9H,1-6,11H2;(H2,1,2,3,4)

HIDE SMILES / InChI
Amantadine hydrochloride has pharmacological actions as both an anti-Parkinson and an antiviral drug. The mechanism by which amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. In certain cases, amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. Data from earlier animal studies suggest that amantadine hydrochloride may have direct and indirect effects on dopamine neurons. More recent studies have demonstrated that amantadine is a weak, non-competitive NMDA receptor antagonist (K1 = 10µM). Although amantadine has not been shown to possess direct anticholinergic activity in animal studies, clinically, it exhibits anticholinergic-like side effects such as dry mouth, urinary retention, and constipation. Amantadine was approved by the FDA in 1966 as a prophylactic agent against Asian influenza, and eventually received approval for the treatment of influenza virus A in adults. In 1969, it was also discovered by accident to help reduce symptoms of Parkinson's disease, drug-induced extrapyramidal syndromes, and akathisia.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MANTADINE HYDROCHLORIDE

Approved Use

Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Launch Date

540518400000
Primary
MANTADINE HYDROCHLORIDE

Approved Use

Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Launch Date

540518400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
636.2 ng/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.24 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6413.6 ng × h/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.7 h
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
33%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources:
healthy, 2
Health Status: healthy
Age Group: 2
Sex: M
Sources:
Disc. AE: Status epilepticus, Agitation...
AEs leading to
discontinuation/dose reduction:
Status epilepticus
Agitation
Diaphoresis
Vomiting
Sources:
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources:
unhealthy, 23
Health Status: unhealthy
Age Group: 23
Sex: M
Sources:
Disc. AE: CNS toxicity...
AEs leading to
discontinuation/dose reduction:
CNS toxicity (grade 5)
Sources:
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
unhealthy, 47
Health Status: unhealthy
Age Group: 47
Sex: F
Sources:
Disc. AE: Ventricular tachycardia...
AEs leading to
discontinuation/dose reduction:
Ventricular tachycardia
Sources:
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 53.3
Health Status: unhealthy
Age Group: 53.3
Sex: M+F
Sources:
Disc. AE: Serotonin syndrome, Dry mouth...
AEs leading to
discontinuation/dose reduction:
Serotonin syndrome (serious, 3.7%)
Dry mouth (3.7%)
Sources:
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
Health Status: unhealthy
Age Group: 63.9
Sex: M+F
Sources:
DLT: Visual hallucinations...
Disc. AE: Visual hallucinations, Peripheral edema...
Dose limiting toxicities:
Visual hallucinations (4.8%)
AEs leading to
discontinuation/dose reduction:
Visual hallucinations (7.9%)
Peripheral edema (4.8%)
Dry mouth (4.8%)
Sources:
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources:
unhealthy, 66.4
Health Status: unhealthy
Age Group: 66.4
Sex: M+F
Sources:
Disc. AE: Hallucinations, Balance disorder...
AEs leading to
discontinuation/dose reduction:
Hallucinations (15%)
Balance disorder (5%)
Confusional state (5%)
Dry mouth (5%)
Subdural hematoma (5%)
Constipation (5%)
Sources:
100 mg 3 times / day steady, oral
Dose: 100 mg, 3 times / day
Route: oral
Route: steady
Dose: 100 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Dry mouth...
Other AEs:
Dry mouth (below serious, 4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Agitation Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources:
healthy, 2
Health Status: healthy
Age Group: 2
Sex: M
Sources:
Diaphoresis Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources:
healthy, 2
Health Status: healthy
Age Group: 2
Sex: M
Sources:
Status epilepticus Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources:
healthy, 2
Health Status: healthy
Age Group: 2
Sex: M
Sources:
Vomiting Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources:
healthy, 2
Health Status: healthy
Age Group: 2
Sex: M
Sources:
CNS toxicity grade 5
Disc. AE
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources:
unhealthy, 23
Health Status: unhealthy
Age Group: 23
Sex: M
Sources:
Ventricular tachycardia Disc. AE
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
unhealthy, 47
Health Status: unhealthy
Age Group: 47
Sex: F
Sources:
Dry mouth 3.7%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 53.3
Health Status: unhealthy
Age Group: 53.3
Sex: M+F
Sources:
Serotonin syndrome serious, 3.7%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 53.3
Health Status: unhealthy
Age Group: 53.3
Sex: M+F
Sources:
Visual hallucinations 4.8%
DLT
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
Health Status: unhealthy
Age Group: 63.9
Sex: M+F
Sources:
Dry mouth 4.8%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
Health Status: unhealthy
Age Group: 63.9
Sex: M+F
Sources:
Peripheral edema 4.8%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
Health Status: unhealthy
Age Group: 63.9
Sex: M+F
Sources:
Visual hallucinations 7.9%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
Health Status: unhealthy
Age Group: 63.9
Sex: M+F
Sources:
Hallucinations 15%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources:
unhealthy, 66.4
Health Status: unhealthy
Age Group: 66.4
Sex: M+F
Sources:
Balance disorder 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources:
unhealthy, 66.4
Health Status: unhealthy
Age Group: 66.4
Sex: M+F
Sources:
Confusional state 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources:
unhealthy, 66.4
Health Status: unhealthy
Age Group: 66.4
Sex: M+F
Sources:
Constipation 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources:
unhealthy, 66.4
Health Status: unhealthy
Age Group: 66.4
Sex: M+F
Sources:
Dry mouth 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources:
unhealthy, 66.4
Health Status: unhealthy
Age Group: 66.4
Sex: M+F
Sources:
Subdural hematoma 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources:
unhealthy, 66.4
Health Status: unhealthy
Age Group: 66.4
Sex: M+F
Sources:
Dry mouth below serious, 4 patients
100 mg 3 times / day steady, oral
Dose: 100 mg, 3 times / day
Route: oral
Route: steady
Dose: 100 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
yes [Ki 111.8 uM]
yes [Ki 1167 uM]
yes [Ki 236 uM]
yes [Ki 284 uM]
yes [Ki >1000 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Blockade of the central effects of d-amphetamine by amantadine. II.
1975 May
Visual hallucinations and delirium during treatment with amantadine (Symmetrel).
1975 May
Efficacy of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide against influenza virus infections in mice.
1975 May
Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.
1991 Dec
Neurotoxicity of chlorpromazine and modulation by amantadine as a function of mouse strain.
1991 Fall
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
1999 Nov
[Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
2000
Amantadine-induced multiple spike waves on an electroencephalogram of a schizophrenic patient.
2000 Jan
Quetiapine for l-dopa-induced psychosis in PD.
2000 Sep 26
Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior.
2001 Jan
Amantadine-induced cortical myoclonus.
2001 Jan 23
A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1.
2001 Jun
Synthesis and pharmacological evaluation of potent and enantioselective sigma 1, and sigma 2 ligands.
2001 Mar
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
2001 May
[L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
2001 May 28
[Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)].
2001 Nov-Dec
Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds.
2002 Oct
NMDA receptor antagonists to characterize rat renal organic cation transporter function.
2002 Sep 27
An artist's view of drug-induced hallucinosis.
2003 Jul
Noncompetitive antagonist binding sites in the torpedo nicotinic acetylcholine receptor ion channel. Structure-activity relationship studies using adamantane derivatives.
2003 Jun 24
Risperidone treatment of motor restlessness following anoxic brain injury.
2003 Mar
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
2003 May 19
Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
2004 Aug
Bitterness evaluation of medicines for pediatric use by a taste sensor.
2004 Aug
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.
2004 Aug
New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
2004 Jun
[Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model].
2004 Mar-Apr
Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C.
2004 May
Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults.
2004 Nov
Prevention of influenza in the general population.
2004 Nov 9
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
2004 Oct
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts.
2006 Feb
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection.
2006 Feb 14
[Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten].
2006 Jul
Interferon signal transduction of biphenyl dimethyl dicarboxylate/amantadine and anti-HBV activity in HepG2 2.2.15.
2006 May
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
2006 Nov
Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.
2006 Sep 15
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
2007 Apr 16
19F NMR detection of the complex between amantadine and the receptor portion of the influenza A M2 ion channel in DPC micelles.
2007 Jul 15
Patents

Sample Use Guides

Uncomplicated Influenza A Virus Illness:
Route of Administration: Oral
Amantadine markedly inhibited the proliferation of HepG2 and SMMC‑7721 cells in a dose‑ and time‑dependent manner and arrested the cell cycle at the G0/G1 phase
Name Type Language
AMANTADINE SULFATE
MART.   MI   WHO-DD  
Common Name English
AMANTADINE SULPHATE (2:1)
Common Name English
1-AMINOADAMANTANE SULPHATE
Systematic Name English
1-ADAMANTANAMINE SULPHATE SALT (2:1)
Common Name English
1-ADAMANTANAMINE SULFATE
Systematic Name English
1-AMINOADAMANTANE SULFATE
Systematic Name English
AMANTADINE SULFATE [WHO-DD]
Common Name English
AMANTADINE SULFATE [MART.]
Common Name English
AMANTADINE SULFATE (2:1)
Common Name English
AMANTADINE SULPHATE
Common Name English
AMANTADINE HEMISULFATE
Common Name English
AMANTADINE SULFATE [MI]
Common Name English
TRICYCLO(3.3.1.19(SUP 3,7))DECAN-1-AMINE
Common Name English
1-ADAMANTANAMINE SULPHATE
Systematic Name English
1-ADAMANTANAMINE SULFATE SALT (2:1)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C281
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
NCI_THESAURUS C93038
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
Code System Code Type Description
FDA UNII
9921T5P019
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY
EVMPD
SUB00423MIG
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY
RXCUI
621
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY RxNorm
PUBCHEM
124108
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY
DRUG BANK
DBSALT000830
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY
MERCK INDEX
M1638
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C90781
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY
CAS
31377-23-8
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY
EVMPD
SUB78132
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY
ECHA (EC/EINECS)
250-604-5
Created by admin on Sat Jun 26 07:42:45 UTC 2021 , Edited by admin on Sat Jun 26 07:42:45 UTC 2021
PRIMARY